The interaction between PAD4 and HIF-1α has been shown to promote breast cancer angiogenesis and tumor growth in animal models and breast cancer patients [254], suggesting that PAD4 inhibition may be a novel treatment strategy for TNBC. Here, HIF1A is linked to breast carcinoma.